LENSAR, Inc. (NASDAQ:LNSR) Sees Significant Drop in Short Interest

LENSAR, Inc. (NASDAQ:LNSR) was the target of a large decrease in short interest in October. As of October 31st, there was short interest totalling 49,800 shares, a decrease of 22.6% from the October 15th total of 64,300 shares. Based on an average daily trading volume, of 31,200 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.6% of the shares of the company are short sold.

Hedge Funds Weigh In On LENSAR

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Brandes Investment Partners LP lifted its position in shares of LENSAR by 12.8% during the 2nd quarter. Brandes Investment Partners LP now owns 373,198 shares of the company’s stock valued at $1,644,000 after acquiring an additional 42,250 shares during the last quarter. DCF Advisers LLC lifted its position in shares of LENSAR by 1.4% during the 2nd quarter. DCF Advisers LLC now owns 241,484 shares of the company’s stock valued at $1,087,000 after acquiring an additional 3,250 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of LENSAR by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 100,431 shares of the company’s stock valued at $460,000 after acquiring an additional 3,423 shares during the last quarter. Finally, Sanctuary Advisors LLC acquired a new stake in shares of LENSAR during the 2nd quarter valued at $93,000. 40.15% of the stock is owned by institutional investors.

LENSAR Stock Down 1.7 %

NASDAQ LNSR traded down $0.12 on Friday, reaching $7.08. 33,734 shares of the stock traded hands, compared to its average volume of 42,733. The firm’s fifty day simple moving average is $5.28 and its 200 day simple moving average is $4.74. The company has a market cap of $82.20 million, a price-to-earnings ratio of -4.85 and a beta of 0.59. LENSAR has a 12 month low of $2.10 and a 12 month high of $7.95.

LENSAR Company Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.